Navigation Links
Products containing specific probes for detecting alternative splice forms protected

ExonHit Therapeutics, today announced the grant of a major patent, US # 6,881,571, by the United States Patent and Trademark Office on microarray products allowing the specific detection of mRNAs produced by alternative splicing, covering microarrays optimised for the discovery of alternative RNA splicing events. The patent protects the probe configuration of a unique set of five oligonucleotides for the detection of each splice variant. There are many applications for this patent, including drug discovery, diagnostics, and compound screenings for efficacy or toxicity as well as screening patients for potential efficacy of therapeutics.

Alternative RNA Splicing is a critical step in the expression of most genes, which can result in the expression of several mRNAs encoding proteins with different functions from a single gene. Splicing events are implicated in numerous pathologies and can be altered by various stress events such as virus, toxic agents, and drug exposure.

The genome-wide patented probe configuration described in the patent is the basis for the microarrays in ExonHit's SpliceArray product line launched earlier this year. The genome profiling market is rapidly growing, and SpliceArrays are the only commercially available microarrays designed to detect alternative splicing. Current SpliceArray products include GPCR, Ion Channel, and Nuclear Receptor family SpliceArrays, as well as custom design services. An Apoptosis and Cytokine gene family array will be launched in the coming months. SpliceArrays are manufactured for ExonHit by Agilent Technologies.

The granting of this patent solidifies ExonHit's leadership in the field of expression profiling and positions the company as the only partner for the conception or use of gene profiling microarrays that include alternative RNA splicing. "The granting of these claims build on the company's core assets further expanding our IP position in the field of gene expression and profiling," sta ted Bruno Tocque, President and CEO, ExonHit Therapeutics. "This is a significant event for ExonHit as we have been quite successful in leveraging strategic assets in multiple arenas, including the therapeutic, diagnostic and research tool markets ?areas in which these claims will further increase our market share."


'"/>

Source:ExonHit


Related biology news :

1. Metal-containing compounds show promise as HIV weapon
2. Preventing a pandemic: Study suggests strategies for containing a flu outbreak
3. Rapid response was crucial to containing the 1918 flu pandemic
4. Scientists generate patient-specific stem cells, Science study says
5. Identification of specific genes predicts which patients will respond to Hepatitis C treatment
6. Eating, body weight regulated by specific neurons
7. Tool developed to silence genes in specific tissues using RNAi
8. Gene-specific Ebola therapies protect non-human primates from lethal disease
9. Unique dual target specificity of kinase inhibitor key for success against cancer
10. Serotonin, acting in a specific brain region, promotes sleep in fruit flies
11. A new male-specific gene in algae unveils an origin of male and female
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/6/2017)... , Jan. 5, 2017  Delta ID Inc., a ... scanning technology for automotive at CES® 2017. Delta ID ... ) to demonstrate the use of iris scanning as ... authenticate the driver in a car, and as a ... driving experience. Delta ID and Gentex will ...
(Date:1/3/2017)... VEGAS , Jan. 3, 2017 Onitor, ... the introduction of Onitor Track, an innovative biometric data-driven ... men, showcasing this month at the 2017 Consumer Electronics ... In the U.S., the World Health ... more than two-thirds of adults who are overweight or ...
(Date:12/20/2016)... Dec. 20, 2016 The rising popularity ... and leasing is stoking significant interest in keyless ... technology, Bluetooth low energy (BLE), biometrics and near-field ... next wave of wireless technologies in the automotive ... to advanced access systems opens the market to ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... ... January 17, 2017 , ... ... research, recently announced a collaboration with the Heidelberg University Hospital and the German ... library preparation, following the company’s successful launch of its CATS (Capture and ...
(Date:1/17/2017)... -- On January 10 at the Medtech Showcase held in ... in San Francisco , ProclaRx CEO, ... pharmaceutical leaders and public and private investors about the ... destroy biofilms.  Biofilms are a physical ... body,s immune system from eradicating chronic infections. Infections with biofilms ...
(Date:1/16/2017)... , Jan. 16, 2017   Valentin A. Pavlov, ... MD , president and CEO of The Feinstein ... an analysis of how the nervous system regulates the ... develop bioelectronic medicine devices to treat disease ... Nature Neuroscience . The paper examines various ...
(Date:1/16/2017)...  Eurofins Genomics today announced the expansion of its ... receive their primers in a shorter turnaround time, without ... with other providers. Express oligos are available for anyone ... no additional fee. Researchers use the oligos ... sequencing, genotyping, site-directed mutagenesis, and cloning. Often, they are ...
Breaking Biology Technology: